BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · IEX Real-Time Price · USD
82.22
+0.09 (0.11%)
At close: Jul 2, 2024, 4:00 PM
82.00
-0.22 (-0.27%)
After-hours: Jul 2, 2024, 5:16 PM EDT
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,401 employees as of December 31, 2023. The number of employees increased by 319 or 10.35% compared to the previous year.
Employees
3,401
Change (1Y)
319
Growth (1Y)
10.35%
Revenue / Employee
$726,740
Profits / Employee
$60,410
Market Cap
15.61B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3,401 | 319 | 10.35% |
Dec 31, 2022 | 3,082 | 37 | 1.22% |
Dec 31, 2021 | 3,045 | -14 | -0.46% |
Dec 31, 2020 | 3,059 | 58 | 1.93% |
Dec 31, 2019 | 3,001 | 152 | 5.34% |
Dec 31, 2018 | 2,849 | 268 | 10.38% |
Dec 31, 2017 | 2,581 | 288 | 12.56% |
Dec 31, 2016 | 2,293 | 135 | 6.26% |
Dec 31, 2015 | 2,158 | 477 | 28.38% |
Dec 31, 2014 | 1,681 | 340 | 25.35% |
Dec 31, 2013 | 1,341 | 252 | 23.14% |
Dec 31, 2012 | 1,089 | 87 | 8.68% |
Dec 31, 2011 | 1,002 | 131 | 15.04% |
Dec 31, 2010 | 871 | 151 | 20.97% |
Dec 31, 2009 | 720 | 71 | 10.94% |
Dec 31, 2008 | 649 | 124 | 23.62% |
Dec 31, 2007 | 525 | 115 | 28.05% |
Dec 31, 2006 | 410 | 96 | 30.57% |
Dec 31, 2005 | 314 | -45 | -12.53% |
Dec 31, 2004 | 359 | 87 | 31.99% |
Dec 31, 2003 | 272 | 53 | 24.20% |
Dec 31, 2002 | 219 | 3 | 1.39% |
Dec 31, 2001 | 216 | 42 | 24.14% |
Dec 31, 2000 | 174 | 25 | 16.78% |
Dec 31, 1999 | 149 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Labcorp Holdings | 67,000 |
Baxter International | 60,000 |
Quest Diagnostics | 48,000 |
Illumina | 13,360 |
BeiGene | 10,600 |
Waters | 7,900 |
Insulet | 3,000 |
Genmab | 2,204 |
BMRN News
- 15 days ago - BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health - PRNewsWire
- 25 days ago - BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress - PRNewsWire
- 7 weeks ago - BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV - PRNewsWire
- 2 months ago - New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting - PRNewsWire
- 2 months ago - BioMarin Reports Record Financial Results for the First Quarter 2024 - PRNewsWire
- 2 months ago - BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET - PRNewsWire
- 4 months ago - New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting - PRNewsWire
- 4 months ago - BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer - PRNewsWire